The pandemic pipeline
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. Companies are doing their best to accelerate experi...
Gespeichert in:
Veröffentlicht in: | Nature biotechnology 2020-05, Vol.38 (5), p.523-532 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 532 |
---|---|
container_issue | 5 |
container_start_page | 523 |
container_title | Nature biotechnology |
container_volume | 38 |
creator | Hodgson, John |
description | Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. |
doi_str_mv | 10.1038/d41587-020-00005-z |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2382657859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2401068068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-3ca7171df9de98413e17942927683f69ee568408645aa3bb5976af799f2a00b33</originalsourceid><addsrcrecordid>eNp9kMtLAzEQh4MotlaPXjxIwYuX1TwnyVGKLyh4qeeQ3Z3VLfty0x7sX2_qVgUPDQMJzDe_DB8hF4zeMCrMbS6ZMjqhnCY0HpVsDsiYKQkJAwuH8U23baZgRE5CWEYGJMAxGQnOqeBWjMn54h2nnW9yrMts2pUdVmWDp-So8FXAs909Ia8P94vZUzJ_eXye3c2TTEq9SkTmNdMsL2yO1kgmkGkrueUajCjAIiowkhqQynuRpspq8IW2tuCe0lSICbkecru-_VhjWLm6DBlWlW-wXQfHheGgtFE2olf_0GW77pu4neNSg1YCKN1PUUbBxIoUH6isb0PosXBdX9a-_3SMuq1aN6h1Ua37Vus2cehyF71Oa8x_R35cRkAMQIit5g37v7_3xH4BAyN_YQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401068068</pqid></control><display><type>article</type><title>The pandemic pipeline</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><creator>Hodgson, John</creator><creatorcontrib>Hodgson, John</creatorcontrib><description>Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/d41587-020-00005-z</identifier><identifier>PMID: 32203293</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antiviral Agents - classification ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Coronavirus Infections - drug therapy ; Coronavirus Infections - prevention & control ; Coronaviruses ; COVID-19 ; Drug Development - economics ; Drug Repositioning ; Drugs ; Humans ; News Feature ; Pandemics ; Pandemics - prevention & control ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - prevention & control ; Time Factors ; Vaccines</subject><ispartof>Nature biotechnology, 2020-05, Vol.38 (5), p.523-532</ispartof><rights>Springer Nature Limited 2020</rights><rights>Nature 2020.</rights><rights>Copyright Nature Publishing Group May 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-3ca7171df9de98413e17942927683f69ee568408645aa3bb5976af799f2a00b33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/d41587-020-00005-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/d41587-020-00005-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32203293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hodgson, John</creatorcontrib><title>The pandemic pipeline</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.</description><subject>Antiviral Agents - classification</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - prevention & control</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Drug Development - economics</subject><subject>Drug Repositioning</subject><subject>Drugs</subject><subject>Humans</subject><subject>News Feature</subject><subject>Pandemics</subject><subject>Pandemics - prevention & control</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - prevention & control</subject><subject>Time Factors</subject><subject>Vaccines</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kMtLAzEQh4MotlaPXjxIwYuX1TwnyVGKLyh4qeeQ3Z3VLfty0x7sX2_qVgUPDQMJzDe_DB8hF4zeMCrMbS6ZMjqhnCY0HpVsDsiYKQkJAwuH8U23baZgRE5CWEYGJMAxGQnOqeBWjMn54h2nnW9yrMts2pUdVmWDp-So8FXAs909Ia8P94vZUzJ_eXye3c2TTEq9SkTmNdMsL2yO1kgmkGkrueUajCjAIiowkhqQynuRpspq8IW2tuCe0lSICbkecru-_VhjWLm6DBlWlW-wXQfHheGgtFE2olf_0GW77pu4neNSg1YCKN1PUUbBxIoUH6isb0PosXBdX9a-_3SMuq1aN6h1Ua37Vus2cehyF71Oa8x_R35cRkAMQIit5g37v7_3xH4BAyN_YQ</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Hodgson, John</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200501</creationdate><title>The pandemic pipeline</title><author>Hodgson, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-3ca7171df9de98413e17942927683f69ee568408645aa3bb5976af799f2a00b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiviral Agents - classification</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - prevention & control</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Drug Development - economics</topic><topic>Drug Repositioning</topic><topic>Drugs</topic><topic>Humans</topic><topic>News Feature</topic><topic>Pandemics</topic><topic>Pandemics - prevention & control</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - prevention & control</topic><topic>Time Factors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hodgson, John</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hodgson, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pandemic pipeline</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>38</volume><issue>5</issue><spage>523</spage><epage>532</epage><pages>523-532</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32203293</pmid><doi>10.1038/d41587-020-00005-z</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1087-0156 |
ispartof | Nature biotechnology, 2020-05, Vol.38 (5), p.523-532 |
issn | 1087-0156 1546-1696 |
language | eng |
recordid | cdi_proquest_miscellaneous_2382657859 |
source | MEDLINE; Springer Nature - Complete Springer Journals; Nature |
subjects | Antiviral Agents - classification Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Coronavirus Infections - drug therapy Coronavirus Infections - prevention & control Coronaviruses COVID-19 Drug Development - economics Drug Repositioning Drugs Humans News Feature Pandemics Pandemics - prevention & control Pneumonia, Viral - drug therapy Pneumonia, Viral - prevention & control Time Factors Vaccines |
title | The pandemic pipeline |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pandemic%20pipeline&rft.jtitle=Nature%20biotechnology&rft.au=Hodgson,%20John&rft.date=2020-05-01&rft.volume=38&rft.issue=5&rft.spage=523&rft.epage=532&rft.pages=523-532&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/d41587-020-00005-z&rft_dat=%3Cproquest_cross%3E2401068068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2401068068&rft_id=info:pmid/32203293&rfr_iscdi=true |